Change over period: —
NSE · GLENMARK
GLENMARK PHA
-1.2% from the 52-week high · +43.7% above the low
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,556 full-time employees. The firm is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The firm also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The firm has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
The short version. GLENMARK PHA reported revenue of ₹4,157 crore for Sep 2026, down 31.3% from a year earlier. Net profit was ₹264 crore (down 56.7% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 46.65% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
GLENMARK PHA trades 1.2% below its 52-week high and 43.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹4,157 cr.
Sep 2026 net profit of ₹264 cr.
3.8 pts lower than a year earlier.
Revenue compounded at 9.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4157 | 4018 | 3771 | 3901 | 6047 | 3264 | 3256 | 3388 |
| Net profit | 264 | 483 | 0 | 403 | 610 | 47 | 5 | 348 |
| Net margin % | 6.3 | 12.0 | -0.0 | 10.3 | 10.1 | 1.4 | 0.1 | 10.3 |
| EPS (₹) | 9.35 | 17.11 | 0.0 | 14.29 | 21.63 | 1.66 | 0.16 | 12.33 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16983 | 13322 | 11813 | 12990 | 12305 | 10944 | 10641 | 9865 |
| Net profit | 1362 | 1047 | -1502 | 297 | 942 | 970 | 776 | 925 |
| Net margin % | 8.0 | 7.9 | -12.7 | 2.3 | 7.7 | 8.9 | 7.3 | 9.4 |
| EPS (₹) | 48.26 | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 | 27.5 | 32.78 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 13.0% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 13.0 | 11.8 | -19.1 | 3.1 |
| Return on capital % | 16.2 | 15.9 | 6.5 | 8.5 |
| EBITDA margin % | 15.9 | 15.6 | 9.0 | 13.8 |
| Net margin % | 7.8 | 7.8 | -11.9 | 2.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.4% | 9.7% |
| Profit CAGR | 66.1% | 7.0% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 2.0 pts over 8 quarters.
Up 3.79 pts over 8 quarters.
+50 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 0.0 |
| FII | 23.51 | 23.16 | 20.62 | 20.73 | 19.2 | 20.34 | 20.89 | 21.51 | -2.0 |
| DII | 13.85 | 14.6 | 17.64 | 18.61 | 20.09 | 19.29 | 18.6 | 17.64 | +3.79 |
| Public | 15.96 | 15.56 | 15.06 | 13.97 | 14.02 | 13.68 | 13.81 | 14.17 | -1.79 |
Mutual fund holdings · Oct 2026
243 schemes hold this stock
193 the month before.
- quant Healthcare Fund9.38% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND5.22% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund5.2% of NAV
- Bandhan Focused Fund4.94% of NAV
- Mirae Asset Healthcare Fund4.61% of NAV
- Invesco India Pharma and Healthcare Fund4.48% of NAV
- Motilal Oswal Quant Fund4.12% of NAV
- quant Large & Mid Cap Fund3.94% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GLENMARK PHA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about GLENMARK PHA
What is the GLENMARK PHA share price?
GLENMARK PHA (GLENMARK) last closed at ₹2,608.50, down 1.42% on the day. Its 52-week range is ₹1,840.80 to ₹2,677.20.
What is the market cap of GLENMARK PHA?
GLENMARK PHA has a market capitalisation of about ₹74,929 crore. Its price-to-earnings ratio is 40.8.
How are GLENMARK PHA's latest results?
GLENMARK PHA reported revenue of ₹4,157 crore for Sep 2026, down 31.3% from a year earlier. Net profit was ₹264 crore (down 56.7% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 46.65% in Sep 2026, up 0.00 points over 8 quarters.
Who owns GLENMARK PHA?
As of Sep 2026, shareholding was: Promoter 46.65%, FII 21.51%, DII 17.64%, Public 14.17%.
How many mutual funds hold GLENMARK PHA?
243 mutual fund schemes held GLENMARK PHA in October 2026. That compares with 193 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 03 Oct 2025 · Interim Dividend - Rs. 2.5
- 15 Sep 2025 · Final Dividend - Rs. 2.5
- 13 Sep 2024 · Final Dividend - Rs. 2.5
- 18 Sep 2023 · Final Dividend - Rs. 2.5
- 12 Sep 2022 · Final Dividend - Rs. 2.5
- 08 Sep 2021 · Final Dividend - Rs. 2.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.